Inaugural Vaccine conference hailed a success
Elsevier celebrates the 25th anniversary of its journal Vaccine
Amsterdam, the Netherlands, 3 January 2008 – Elsevier, world-leading publisher of scientific, technical and medical information products and services, organized a conference last month to celebrate the 25th anniversary of its journal Vaccine. With over 350 delegates in attendance from 36 countries and over 70 papers being presented, the stage was set for a landmark 2.5 days in the advancement of the vaccine field.
Vaccine, the pre-eminent journal for researchers interested in vaccines and vaccination, has evolved from a quarterly publication in the early 1980’s into a weekly publication now. It serves as an interface between academics, those in research and development, regulatory and governmental agencies, charities, and health and industry professionals in the field.
In his opening address Youngsuk (YS) Chi, Vice Chairman Elsevier, stated: “The vaccine field has become increasingly multi-dimensional and interdisciplinary, and the conference successfully reflects this trend”.
Especially the recently stopped HIV vaccine STEP trial was a recurring topic during various sessions of the conference. Vaccination is seen as one of the most promising approaches of halting the HIV/AIDS epidemic and the recently published interim results, showing that the vaccine was not effective and did not prevent infection, were discussed during the conference from the science, health and policy perspectives.
Elsevier is looking forward to continuing and strengthening its relationship with the vaccine community, and is delighted to announce that the next Vaccine conference will be held in early December 2008 in Boston, Massachusetts, USA.
# # #
Elsevier is a world-leading provider of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals, including The Lancet and Cell, and close to 20,000 book titles, including major reference works from Mosby and Saunders. Elsevier’s online solutions include ScienceDirect, Scopus, SciVal, Reaxys, ClinicalKey and Mosby’s Suite, which enhance the productivity of science and health professionals, helping research and health care institutions deliver better outcomes more cost-effectively.
A global business headquartered in Amsterdam, Elsevier employs 7,000 people worldwide. The company is part of Reed Elsevier Group plc, a world leading provider of professional information solutions. The group employs more than 30,000 people, including more than 15,000 in North America. Reed Elsevier Group plc is owned equally by two parent companies, Reed Elsevier PLC and Reed Elsevier NV. Their shares are traded on the London, Amsterdam and New York Stock Exchanges using the following ticker symbols: London: REL; Amsterdam: REN; New York: RUK and ENL.
Floris de Hon
+31 20 485 2498